Drugs / Personalized NeoAntigen Peptides
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02287428 | Nov 2014 → Feb 2027 expected | glioblastoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized NeoAntigen Peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02287428 ↗ |
| Modality | Vaccine | “NeoVax Vaccine (Personalized NeoAntigen Peptides + Poly-ICLC)” NCT02287428 ↗ |